TNGNQ (Tengion) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


What is Tengion Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Tengion's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TNGNQ vs VITIF, HSTC, NTRR: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Tengion's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tengion Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Tengion's Margin of Safety % (DCF Earnings Based) falls into.


Tengion Business Description

Address 3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.